Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accounts Payables: 2017-2024

Historic Accounts Payables for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $4.7 million.

  • Aclaris Therapeutics' Accounts Payables rose 19.90% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 19.90%. This contributed to the annual value of $4.7 million for FY2024, which is 47.17% down from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Accounts Payables is $4.7 million, which was down 47.17% from $8.9 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Accounts Payables registered a high of $10.4 million during FY2022, and its lowest value of $4.7 million during FY2024.
  • Its 3-year average for Accounts Payables is $8.0 million, with a median of $8.9 million in 2023.
  • In the last 5 years, Aclaris Therapeutics' Accounts Payables surged by 90.05% in 2021 and then slumped by 47.17% in 2024.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Accounts Payables stood at $5.3 million in 2020, then soared by 90.05% to $10.0 million in 2021, then grew by 3.67% to $10.4 million in 2022, then declined by 14.23% to $8.9 million in 2023, then tumbled by 47.17% to $4.7 million in 2024.